1 Day
Source:
المواطن
_1777294237270_124456903.png&w=48&q=75){kind=small}
Food and Drug Authority approves Foundayo for obesity
The General Authority for Food and Drug Administration has approved the registration of the medication "Vondaio" for the treatment of obesity and weight gain. It is intended to be used alongside a healthy diet and physical activity. The medication contains the active ingredient orforglieberon and works by activating glucagon-like peptide receptors, which reduces appetite and significantly aids in weight loss. Clinical studies have shown that a 36 mg dose can lead to an average weight reduction of between 9.6% and 11.2% over 72 weeks. Side effects may include mild to moderate gastrointestinal disturbances such as nausea, diarrhea, and vomiting. It is emphasized that the medication should be used under medical supervision with ongoing monitoring, and there is a warning against its use in individuals with a family or personal history of thyroid tumors.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)